Search clinical trials for: PARP inhibitor BMN-673

Total 1884 results

Jonsson Comprehensive Cancer Center
Medivation, Inc.; BioMarin Pharmaceutical; Translational Research in Oncology

Completed

PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Metastatic Cancer | Unspecified Adult Solid Tumor

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Metastatic Malignant Neoplasm | Advanced Malignant Neoplasm | Recurrent Malignant Neoplasm | Refractory Malignant Neoplasm | PALB2 Gene Mutation | ATM Gene Mutation

United States
National Cancer Institute (NCI)

Withdrawn

Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Stage IV Non-Small Cell Lung Cancer | Metastatic Pancreatic Adenocarcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast... and other conditions
National Cancer Institute (NCI)

Withdrawn

Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Ovarian Serous Adenocarcinoma | Primary Peritoneal... and other conditions
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer

Invasive Breast Carcinoma | HER2/Neu Negative | Breast Adenocarcinoma | Deleterious BRCA1 Gene Mutation | Deleterious BRCA2 Gene Mutation

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7 | BRIP1 Gene Mutation | PALB2 Gene Mutation | ATM Gene Mutation | ATR Gene Mutation | CHEK2 Gene Mutation | NBN Gene Mutation | RAD51 Gene Mutation | CHEK1 Gene Mutation | FANCA Gene... and other conditions

United States, Canada
Roswell Park Cancer Institute
Pfizer

Active, not recruiting

Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
National Cancer Institute (NCI)

Completed

Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations

Advanced Breast Cancer | Advanced Solid Tumors | Primary Peritoneal Cancer | Advanced Ovarian Cancer

United States
Pfizer

Completed

Study of BMN 673, a PARP Inhibitor, in Healthy Adult Male Volunteers

Human Volunteers

United States
University College, London
Medivation, Inc.

Withdrawn

A Parp Inhibitor (BMN 673) for Inoperable Advanced eNDometrial cAncer (PANDA)

Endometrial Cancer

United Kingdom
Pfizer
Medivation, Inc.

Completed

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Breast Neoplasms | Small Cell Lung Carcinoma | Prostate Cancer | Ewing Sarcoma | Pancreas Cancer | Ovarian Cancer, Epithelial | Advanced or Recurrent Solid Tumors

United States, United Kingdom
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Recurrent Lung Non-Squamous Non-Small Cell Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Carcinoma | Stage IV Uterine Corpus Cancer AJCC v8 | Stage IVA Uterine Corpus Cancer AJCC v8 | Stage IVB Uterine Corpus Cancer AJCC v8 | Recurrent Cervical Carcinoma | Malignant... and other conditions

United States
Melinda Telli
Pfizer; BioMarin Pharmaceutical

Completed

Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors

Advanced Breast Cancer | HER2/Neu Negative | Triple-Negative Breast Cancer

United States
Stanford University
Pfizer

Recruiting

Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer

Breast Cancer | Advanced Breast Cancer

United States
Pfizer
Medivation, Inc.

Completed

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies

Acute Myeloid Leukemia | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Myelodysplastic Syndrome

United Kingdom, United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (POSITION)

Fallopian Tube Serous Adenocarcinoma | Primary Peritoneal Serous Adenocarcinoma | Stage III Fallopian Tube Cancer AJCC v7 | Stage III Ovarian Cancer AJCC v6 and v7 | Stage III Primary Peritoneal Cancer AJCC v7 | Stage IIIA Fallopian Tube Cancer AJCC v7 | Stage IIIA Ovarian Cancer AJCC v6 and v7 | Stage IIIA Primary Peritoneal Cancer AJCC v7 and other conditions

United States
National Cancer Institute (NCI)

Terminated

BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment

Ovarian Cancer

United States
Memorial Sloan Kettering Cancer Center

Completed

Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma

Metastatic Renal Cell Carcinoma | Fumarate Hydratase Deficient Renal Cell Carcinoma | Succinate Dehydrogenase Deficient Renal Cell Carcinoma

United States
Jonsson Comprehensive Cancer Center
Pfizer; Translational Research in Oncology

Recruiting

Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer

Recurrent Extensive Stage Small Cell Lung Carcinoma | Refractory Extensive Stage Small Cell Lung Carcinoma

United States
Pfizer

Terminated

Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors

Locally Advanced or Metastatic Solid Tumors | Genes, BRCA 1

United States, Belgium, Spain, Denmark, Japan, France, Italy, Netherlands, United Kingdom
National Cancer Institute (NCI)

Completed

Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies

Recurrent Malignant Solid Neoplasm | Childhood Solid Neoplasm | Recurrent Childhood Central Nervous System Neoplasm | Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Adult Solid Neoplasm | Refractory Central Nervous System Neoplasm

United States
Pamela Munster
QuantumLeap Healthcare Collaborative

Terminated

Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer

Triple Negative Metastatic Breast Cancer | BRCA-mutated Solid Tumor

United States
M.D. Anderson Cancer Center

Not yet recruiting

Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer

Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced Cancer

Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
St. Jude Children's Research Hospital
Pfizer; Ipsen

Recruiting

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Refractory Malignant Solid Neoplasm | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma | Recurrent Osteosarcoma | Recurrent Peripheral Primitive Neuroectodermal Tumor | Recurrent Rhabdoid Tumor | Recurrent... and other conditions

United States, Canada
Annu Navani
Andrews Research & Education Foundation

Completed

The Use of PRP and BMC in Patients With Internal Disc Disruption Multicenter Prospective Randomized Controlled Trial in Patients With Internal Disc Disruption

Internal Disc Disruption

United States
Pfizer

Terminated

A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors

Pancreatic Cancer

Belgium, United States, Singapore
University of Leeds

Active, not recruiting

Tibial Fracture - Platelet-rich Plasma and Bone Marrow Concentrate (T-PAC)

Unilateral Tibial Diaphyseal Fracture

United Kingdom
National Taiwan University Hospital
National Taiwan University Hospital, Yun-Lin Branch

Recruiting

Regorafenib Plus Tislelizumab as First-line Systemic Therapy for Patients With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

Taiwan
ViiV Healthcare
GlaxoSmithKline

Terminated

A Study to Determine the Effect of Multiple Doses of BMS-955176 on the Electrocardiograph of Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
Leiden University Medical Center
Radboud University Medical Center; AstraZeneca; University Medical Center Groningen and other collaborators

Active, not recruiting

Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer (DOMEC)

Uterine Neoplasms | Endometrial Neoplasms | Endometrium Cancer

Netherlands
SWOG Cancer Research Network
National Cancer Institute (NCI)

Completed

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7

United States, Canada
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI); BeiGene

Completed

BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations

Recurrent Glioblastoma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II Glioma | IDH1 Mutation | IDH2 Mutation

United States
Hellenic Cooperative Oncology Group

Active, not recruiting

Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer

Ovarian Cancer

Greece
National Cancer Institute (NCI)

Recruiting

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Pancreatic Carcinoma | Metastatic Pancreatic Carcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Castration-Resistant Prostate Carcinoma and other conditions

United States
Tianjin Medical University Cancer Institute and...

Recruiting

PD1 and PARP for Maintenance Therapy in NSLLC

Lung Cancer

China
Bristol-Myers Squibb

Completed

Study to Evaluate Safety and Efficacy in Adult Subjects With ITP (ITP)

Immune Thrombocytopenic Purpura

United States, Australia, United Kingdom, Canada, Georgia, Moldova, Republic of, Poland, Russian Federation
Bristol-Myers Squibb

Terminated

Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV (DIMENSION)

Chronic Hepatitis C Infection

France, Germany, United States, Spain, Canada, Argentina, Mexico, Belgium, Italy, Russian Federation, United Kingdom, Poland
Allarity Therapeutics
Danish Breast Cancer Cooperative Group; Smerud Medical Research International...

Active, not recruiting

Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP

Metastatic Breast Cancer

Denmark
Xiaoxiang Chen

Not yet recruiting

Homologous Recombination Deficiency in Chinese Ovarian Cancer Patients (HOPEI)

Ovarian Cancer | HRD | PARP Inhibitor

China
National Cancer Institute (NCI)

Recruiting

Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial

Malignant Solid Neoplasm | Adrenal Gland Pheochromocytoma | Paraganglioma | Hematopoietic and Lymphatic System Neoplasm

United States
Pfizer

Terminated

Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors

United States, Canada, United Kingdom, Korea, Republic of, Australia, Belgium, Denmark, Hungary, Russian Federation
St. Jude Children's Research Hospital
Pfizer; BioMarin Pharmaceutical; Alliance Pharma

Completed

Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies

Childhood Solid Tumors

United States
Washington University School of Medicine
BioMarin Pharmaceutical

Withdrawn

Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors

Non-Small Cell Lung Cancer | Nonsmall Cell Lung Cancer | Solid Tumors | Carcinoma, Non-Small Cell Lung | Non-Small-Cell Lung Carcinoma
Shanghai Mental Health Center
Jiangsu Kanion Pharmaceutical Co.

Unknown

Tolerance, PK and PD Effects Study of TPN-672 in Chinese Healthy Volunteers

PHA1A

China
Northwestern University
Bristol-Myers Squibb; National Cancer Institute (NCI); AbbVie

Unknown

Nivolumab and Veliparib in Treating Patients With Recurrent or Refractory Stage IV Solid Tumors That Cannot Be Removed by Surgery or Lymphoma With or Without Alterations in DNA Repair Genes

Unresectable Solid Neoplasm | Recurrent Solid Neoplasm | Refractory Mantle Cell Lymphoma | Aggressive Non-Hodgkin Lymphoma | Advanced Solid Neoplasm | T-Cell Non-Hodgkin Lymphoma

United States
AstraZeneca

Completed

A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)

Ovarian Neoplasms | BRCA1 Protein | BRCA2 Protein

Netherlands, Belgium, United Kingdom, Poland
AstraZeneca
KuDOS Pharmaceuticals Limited

Completed

Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer (ICEBERG 2)

Ovarian Neoplasm

United States, Spain, Australia, Germany, Sweden

Search clinical trials for: PARP inhibitor BMN-673

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Paraguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations